Clinical trial
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With…
NCT00048620 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00048620 |
|---|---|
| Title | Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI |
| Official title | Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis VI |
| Intervention type | Drug |
| Interventions | N-acetylgalactosamine 4-sulfatase |
| Start date | Sep 1, 2000 |
| Completion | Nov 1, 2005 |
| First posted | Nov 6, 2002 |
| Last update posted | Nov 3, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: